Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
CRSP · Why this verdict
Why CRISPR Therapeutics (CRSP) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
A high-growth biotech with approximately 69% revenue expansion and significant analyst-implied upside that is simultaneously running a deeply negative cash burn, trading in a confirmed downtrend below a declining 200-day average, and carrying 26% short interest — a high-risk, binary-outcome setup where execution consistency must improve before the risk/reward becomes actionable.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock is trading below its 200-day moving average, which itself is declining at approximately 1.7% per month, forming a pattern of persistent selling pressure that typically warrants waiting for a technical recovery before establishing or adding to a position. Momentum breakdown | A recovery above the 200-day moving average, with the moving average slope turning flat or positive, would remove this technical headwind and signal a more constructive entry environment. | →Stable |
| CounterOn-balance volume is rising despite the declining price trend — a divergence that historically can precede technical reversals, suggesting buyers may be quietly accumulating beneath the surface. | ||
Free cash flow is negative at a rate more than sixty times annual revenue, and the Piotroski financial health score of 4.4 indicates only modest balance-sheet resilience; without an imminent revenue catalyst, cash runway risk is a material concern for existing holders. Quality breakdown | Free cash flow deficit narrows to less than 500% of revenue for 2 consecutive quarters, demonstrating that commercial revenue is beginning to meaningfully offset cash outflows. | →Stable |
| CounterThe current ratio reflects adequate near-term liquidity, and if a commercial launch accelerates revenue sharply, the cash conversion ratio can improve from its current extreme level in relatively short order. | ||
Short interest of 26% combined with an elevated put-to-call ratio of 2.00 reflects substantial institutional conviction that the stock will decline — a configuration that can amplify downside on any negative catalyst and requires a strong fundamental counter-narrative to resolve. Risk breakdown | Short interest falls below 15% over 12 months as the fundamental trajectory improves and short sellers begin to cover. | →Stable |
| CounterHigh short interest in cash-burning biotechs can partly reflect hedged positions by convertible debt holders or institutional arbitrageurs rather than purely directional bearish bets, which may overstate the net pessimism in the market. | ||
Revenue has grown approximately 69% year-over-year, placing the company among the top growth names in its peer group, and analysts project approximately 59% additional upside from the current price — suggesting the market has not fully priced a successful commercial ramp. Growth breakdown | Revenue sustains above 40% year-over-year growth for 4 consecutive quarters, providing tangible commercial momentum that supports the current analyst target. | →Stable |
| CounterThe growth figure carries limited confidence given sparse coverage, and back-to-back earnings misses in the two most recent quarters suggest the actual commercial ramp is tracking below initial expectations. | ||
The stock is trading below its 200-day moving average, which itself is declining at approximately 1.7% per month, forming a pattern of persistent selling pressure that typically warrants waiting for a technical recovery before establishing or adding to a position.
→StableMomentum breakdown
- Expectation
- A recovery above the 200-day moving average, with the moving average slope turning flat or positive, would remove this technical headwind and signal a more constructive entry environment.
CounterOn-balance volume is rising despite the declining price trend — a divergence that historically can precede technical reversals, suggesting buyers may be quietly accumulating beneath the surface.
Free cash flow is negative at a rate more than sixty times annual revenue, and the Piotroski financial health score of 4.4 indicates only modest balance-sheet resilience; without an imminent revenue catalyst, cash runway risk is a material concern for existing holders.
→StableQuality breakdown
- Expectation
- Free cash flow deficit narrows to less than 500% of revenue for 2 consecutive quarters, demonstrating that commercial revenue is beginning to meaningfully offset cash outflows.
CounterThe current ratio reflects adequate near-term liquidity, and if a commercial launch accelerates revenue sharply, the cash conversion ratio can improve from its current extreme level in relatively short order.
Short interest of 26% combined with an elevated put-to-call ratio of 2.00 reflects substantial institutional conviction that the stock will decline — a configuration that can amplify downside on any negative catalyst and requires a strong fundamental counter-narrative to resolve.
→StableRisk breakdown
- Expectation
- Short interest falls below 15% over 12 months as the fundamental trajectory improves and short sellers begin to cover.
CounterHigh short interest in cash-burning biotechs can partly reflect hedged positions by convertible debt holders or institutional arbitrageurs rather than purely directional bearish bets, which may overstate the net pessimism in the market.
Revenue has grown approximately 69% year-over-year, placing the company among the top growth names in its peer group, and analysts project approximately 59% additional upside from the current price — suggesting the market has not fully priced a successful commercial ramp.
→StableGrowth breakdown
- Expectation
- Revenue sustains above 40% year-over-year growth for 4 consecutive quarters, providing tangible commercial momentum that supports the current analyst target.
CounterThe growth figure carries limited confidence given sparse coverage, and back-to-back earnings misses in the two most recent quarters suggest the actual commercial ramp is tracking below initial expectations.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 5.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -6359% of revenue
- ▸No competitive moat
- ▸Quality concerns
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 69% YoY
Momentum
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 8.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 3.5 |
| Analyst rating | 7.5 |
| Price target | 9.5 |
- ▸Analyst upside: 49%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Negligible insider selling — $210,577 (0.004% of mkt cap)
Peer rank
4.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 4.8 |
| growth rank | 7.4 |
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.8 |
| support resistance | 3.1 |
| 52w position | 4.2 |
| gap | 5.0 |
Risk (lower is worse)
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.9 |
| days to cover | 0.0 |
| volatility | 0.1 |
| put call | 5.0 |
| implied vol | 1.6 |
| max pain risk | 3.0 |
| beta | 4.3 |
| debt equity | 8.3 |
- ▸High short interest justified: 26%
- ▸High IV: 70%
- ▸Above max pain $30
Catalyst
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 2.7 |
| news activity | 7.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:4.9>=4.5
- ASYMMETRY:2.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:46d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- MOMENTUM:4.9<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
2.80
Upside
+34.5%
Downside
12.3%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 47
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 1.70>1.3
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: DEATH_CROSS:HARD_BLOCK.
The strongest dimensions are Growth at 10.0, Value at 9.0, and Sentiment at 6.8; the weakest are Quality at 1.8, Risk (lower is worse) at 2.9, and Technical at 3.5. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 2.80 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The stock is trading below its 200-day moving average, which itself is declining at approximately 1.7% per month, forming a pattern of persistent selling pressure that typically warrants waiting for a technical recovery before establishing or adding to a position.
Trip ifStock breaks above the 200-day moving average and holds above it for 10 consecutive trading days with the moving average slope turning flat or positive.
- P2Free cash flow is negative at a rate more than sixty times annual revenue, and the Piotroski financial health score of 4.4 indicates only modest balance-sheet resilience; without an imminent revenue catalyst, cash runway risk is a material concern for existing holders.
Trip ifFree cash flow deficit narrows to less than 500% of revenue for 2 consecutive quarters.
- P3Short interest of 26% combined with an elevated put-to-call ratio of 2.00 reflects substantial institutional conviction that the stock will decline — a configuration that can amplify downside on any negative catalyst and requires a strong fundamental counter-narrative to resolve.
Trip ifShort interest falls below 15% of the float for 3 consecutive months.
- P4Revenue has grown approximately 69% year-over-year, placing the company among the top growth names in its peer group, and analysts project approximately 59% additional upside from the current price — suggesting the market has not fully priced a successful commercial ramp.
Trip ifRevenue growth falls below 25% YoY for 2 consecutive quarters, indicating commercial momentum has stalled.